Nurse Practitioner · Atlanta, GA
NPI
1831268630
Since 2006
Specialty
Nurse Practitioner
Code 363L00000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
2140 Peachtree Rd NW, Suite 232
Atlanta, GA, 30309
Phone (404) 231-4431
Groups this clinician bills Medicare through
Medicare paid, 2024
$22K
822 services
Medicare patients, 2024
38
Average age 67
Drug cost, 2024
$4.1M
3,265 prescriptions
Company payments, 2025
$1,002
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark G Hebert was code 87536 (infectious agent detection by dna/rna), 88 times for 34 patients. In total Mark G Hebert billed 822 services in 48 codes, and Medicare paid $22K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-06-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 87536 Infectious Agent Detection by DNA/RNA | Office | 88 | 34 | $83.40 | $7,339 |
| 85025 Blood Count | Office | 84 | 35 | $7.61 | $639 |
| 80053 Clinical Chemistry | Office | 83 | 36 | $10.35 | $859 |
| 80061 Clinical Chemistry | Office | 52 | 30 | $13.12 | $682 |
| 36415 Venipuncture Blood Collection | Office | 32 | 21 | $8.65 | $277 |
| 83036 Blood Count | Office | 30 | 19 | $9.52 | $286 |
| 82306 Clinical Chemistry | Office | 26 | 23 | $29.01 | $754 |
| 82043 Clinical Chemistry | Office | 24 | 16 | $5.66 | $136 |
| 90480 Vaccine Administration | Office | 23 | 20 | $42.73 | $983 |
| 81003 Clinical Chemistry | Office | 21 | 18 | $2.20 | $46.2 |
| G0008 Administration of influenza virus vaccine | Office | 20 | 18 | $32.05 | $641 |
| 86592 Immunoassay | Office | 19 | 14 | $4.18 | $79.42 |
| 91322 Vaccine Product | Office | 19 | 18 | $156.80 | $2,979 |
| 90471 Vaccine Administration | Office | 18 | 18 | $5.35 | $96.25 |
By year: 2022 $3,669 for 137 services; 2023 $9,687 for 682 services; 2024 $22K for 822 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 87536 Infectious Agent Detection by DNA/RNA | 88 | 34 | $83.40 | $7,339 |
| 85025 Blood Count | 84 | 35 | $7.61 | $639 |
| 80053 Clinical Chemistry | 83 | 36 | $10.35 | $859 |
| 80061 Clinical Chemistry | 52 | 30 | $13.12 | $682 |
| 36415 Venipuncture Blood Collection | 32 | 21 | $8.65 | $277 |
| 83036 Blood Count | 30 | 19 | $9.52 | $286 |
| 82306 Clinical Chemistry | 26 | 23 | $29.01 | $754 |
| 82043 Clinical Chemistry | 24 | 16 | $5.66 | $136 |
| 81003 Clinical Chemistry | 21 | 18 | $2.20 | $46.2 |
| 86592 Immunoassay | 19 | 14 | $4.18 | $79.42 |
Medicare prescription drug claims, 2024
In 2024, the drug Mark G Hebert prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 341 prescriptions and refills. In total Mark G Hebert wrote 3,265 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 341 | 349 | 33 | $1.3M |
| Dovato Dolutegravir Sodium/Lamivudine | 128 | 128 | 15 | $366K |
| Rosuvastatin Calcium Generic | 124 | 232 | 27 | $627 |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 113 | 123 | 11 | $474K |
| Atorvastatin Calcium Generic | 98 | 186 | 26 | $409 |
| Descovy Emtricitabine/Tenofov Alafenam | 94 | 94 | Under 11 | $192K |
| Valacyclovir Valacyclovir Hcl | 93 | 127 | 15 | $1,771 |
| Prezcobix Darunavir/Cobicistat | 74 | 74 | Under 11 | $174K |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 74 | 74 | Under 11 | $336K |
| Amlodipine Besylate Generic | 71 | 129 | 13 | $191 |
| Zolpidem Tartrate Generic | 69 | 75 | Under 11 | $368 |
| Lisinopril Generic | 65 | 119 | 14 | $214 |
| Tivicay Dolutegravir Sodium | 64 | 64 | Under 11 | $172K |
| Isentress Raltegravir Potassium | 60 | 60 | Under 11 | $109K |
| Gabapentin Generic | 59 | 85 | 13 | $363 |
Brand drugs: - claims; generic drugs: 1,950 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark G Hebert $1,002 ($1,002 in general payments such as food, travel and fees) from 9 companies. The largest payer was ViiV Healthcare Company with $458.
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company GSK | 25 | $458 |
| Gilead Sciences, Inc. GILD | 8 | $188 |
| Merck Sharp & Dohme LLC MRK | 6 | $135 |
| Novo Nordisk Inc NVO | 3 | $54.86 |
| Verity Pharmaceuticals Inc. | 3 | $47.77 |
| Theratechnologies Inc. THTX | 2 | $45.38 |
| Exact Sciences Corporation EXAS | 2 | $30.35 |
| Abbott Laboratories ABT | 1 | $22.05 |
| Napo Pharmaceuticals Inc | 1 | $20.85 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.